3Editorial. The statin wars: Astra Zeneca must retreat[J]. Lancet, 2003, 362 (9393): 1341 被引量：1
4Corsini A. The Safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk[J]. Cardiovasc Drug Ther, 2003, 17 (3): 265 被引量：1
5Kajinami K, Takekoshi N, Saito Y L. Pitavastatin: efficacy and safety profiles of a novel synthetit HMG-CoA reductase inhibitor [J] .Cardiovasc Drug Rev, 2003, 21 (3): 199 被引量：1
6Grundy S M. The issue of statin safety-where do we stand?[J] . Circulation. 2005, 111: 3016 被引量：1
10Kimura M, Kurose I, Russell J, et al. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemia rats [J]. Arteripscler Thromb Vase Biol, 1997, 17:1521 被引量：1
3Davidison MH.Rosuvastatin:a highly efficacious statin for the treatment of dyslipidemia[J].Expert Opin Investig Durgs , 2002,11 : 125. 被引量：1
4Gonzalez ML, Gonzalez Ruiz M, Duvos E, et al. Atorvastatin - induced severe thrombocy topenia [J]. Lancet,1998,352(9 136) : 1284. 被引量：1
5Monika L,Fritz H,Gunther K,et al .Depressive symptoms in hypercholesterolaemic patients treated with prav astatin[J]. Lancet, 1992, a40(8 824) : 910. 被引量：1
6Stein E Results of phase Ⅰ /Ⅱ clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor[J].Eur Heart J Supplements, 2001, 31( 1): 11. 被引量：1
7Bays HE, Moore PB, Orehobl MA, et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase Ⅱ studies[J].Clin Ther, 2001, 23( 5): 1 029. 被引量：1
9Lamarche B, Tchemof A, Moorjani S, et al. Small dense LDL particle as a predictor of ischemic heart disease in men[J].Circulation, 1997, 95( 1): 96. 被引量：1
10Scandinavian Simvastatin Survival Study Group Rand- omised trial of cholesterol lowering in 4 444 patients with coronary heart disease; the Scandinavian Simvast- atin Survival Study 4S[J].Lancet, 1994, 344( 6): 1 383. 被引量：1
